Table 4 Performance of the ADNEX model in polytomous discriminations between different types of adnexal masses according to whether CA 125 level was included in the model

Benign vs. Malignant

0.97 (0.96–0.98)

0.97 (0.95–0.98)

0.07

Benign vs. BOT

0.94 (0.92–0.97)

0.94 (0.91–0.97)

0.19

Benign vs. Stage I OC

0.98 (0.97–0.99)

0.98 (0.96–0.99)

0.21

Benign vs. Stage II–IV OC

0.99 (0.99–1.00)

0.99 (0.99–1.00)

0.03

Benign vs. Metastasis

0.99 (0.98–1.00)

0.99 (0.97–1.00)

0.24

BOT vs. Stage I OC

0.54 (0.45–0.64)

0.50 (0.41–0.60)

0.10

BOT vs. Stage II–IV OC

0.92 (0.88–0.97)

0.89 (0.88–0.97)

0.06

BOT vs. Metastasis

0.66 (0.56–0.77)

0.52 (0.29–0.75)

0.34

Stage I OC vs. Stage II–IV OC

0.94 (0.88–0.99)

0.88 (0.80–0.96)

0.01

Stage I OC vs. Metastasis

0.72 (0.60–0.85)

0.54 (0.21–0.86)

0.37

Stage II–IV OC vs. Metastasis

0.97 (0.93–1.00)

0.86 (0.76–0.95)

0.01